NSE:GLAND

Gland Pharma Names Dr. Reddy's Executive as CEO

Gland Pharma (NSE:GLAND, BOM:543245) appointed Deepak Sapra as its new chief executive officer, effective Nov. 16.Sapra currently serves as CEO of API and Services at Dr. Reddy's Laboratories (NSE:DRREDDY, BOM:500124), according to an Indian bourse filing on Friday.Shares of the company rose over 1% in recent trade.

Nomura Adjusts Gland Pharma's Price Target to INR3,330 From INR2,390, Keeps at Buy

Gland Pharma (NSE:GLAND, BOM:543245) has an average rating of overweight and mean price target of 2,845.07 Indian rupees, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

Jefferies Upgrades Gland Pharma to Buy From Hold, Adjusts Price Target to INR3,350 From INR2,080

Gland Pharma (NSE:GLAND, BOM:543245) has an average rating of overweight and mean price target of 2,603.08 Indian rupees, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

Kotak Securities Upgrades Gland Pharma to Add From Reduce; Price Target is INR2,075

Nomura Adjusts Gland Pharma's Price Target to INR2,390 from INR2,000, Keeps at Buy

Jefferies Adjusts Gland Pharma's Price Target to INR2,080 from INR1,720, Keeps at Hold

Gland Pharma's Consolidated Attributable Profit Almost Doubles in Fiscal Q4

Gland Pharma's (NSE:GLAND, BOM:543245) attributable consolidated profit almost doubled to 3.67 billion Indian rupees in the fiscal fourth quarter from 1.87 billion rupees a year ago.Earnings per share jumped to 22.23 rupees from 11.32 rupees over the period, according to a Friday filing to the Indian stock exchanges by the pharmaceutical company.Revenue from operations during the quarter also increased to 17.43 billion rupees from 14.25 billion rupees a year earlier.The company's board recommended a final dividend of 20 rupees per share for the financial year ended March 31.